Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 295, Issue 5, 2008, Pages

  Rastogi, Sharad ^a   Sharov, Victor G ^a   Mishra, Sudhish ^a   Gupta, Ramesh C ^a   Blackburn, Brent ^c   Belardinelli, Luiz ^c   Stanley, William C ^b   Sabbah, Hani N ^a,d  

^a HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c CV THERAPEUTICS INC   (United States)

^d HENRY FORD HOSPITAL   (United States)

Author keywords

Left ventricle; Sodium current; Transcription factors; Ventricular remodeling

Indexed keywords

CALCIUM; ENALAPRIL; METOPROLOL TARTRATE; PLACEBO; RANOLAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL EMBOLISM; CAPILLARY DENSITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DOG; DRUG EFFECT; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICULOGRAPHY; MONOTHERAPY; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACETANILIDES; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOGS; DRUG THERAPY, COMBINATION; ENALAPRIL; HEART FAILURE; METOPROLOL; MYOCARDIUM; PIPERAZINES; PROTEINS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 57049182027     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00728.2008     Document Type: Article

References (49)

1. Bagger JP, Botker HE, Thomassen A, Nielsen TT. Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease. Cardiovasc Drugs Ther 11: 479-484, 1997.
2. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 92, Suppl 4: iv6 -iv14, 2006.
3. Bers DM. Excitation-Contraction Coupling and Cardiac Contractile Force. Dordrecht, The Netherlands: Kluwer Academic, 2001.
4. Buitrago M, Lorenz K, Maass AH, Oberdorf-Maass S, Keller U, Schmitteckert EM, Ivashchenko Y, Lohse MJ, Engelhardt S. The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy. Nat Med 11: 837-844, 2005.
5. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291: 309-316, 2004.
6. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff AA. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43: 1375-1382, 2004.
7. Chandler MP, Stanley WC, Morita H, Suzuki G, Roth BA, Blackburn B, Wolff A, Sabbah HN. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res 91: 278-280, 2002.
8. Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clanachan AS. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol 41: 1031-1038, 2006.
9. Gengo PJ, Sabbah HN, Steffen RP, Sharpe JK, Kono T, Stein PD, Goldstein S. Myocardial beta adrenoceptor and voltage sensitive calcium channel changes in a canine model of chronic heart failure. J Mol Cell Cardiol 24: 1361-1369, 1992.
10. Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA. Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol 44: 954-967, 2008.
11. 2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 99: 641-648, 1999.
12. Imai M, Rastogi S, Gupta RC, Mishra S, Sharov VG, Stanley WC, Mika Y, Rousso B, Burkhoff D, Ben-Haim S, Sabbah HN. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J Am Coll Cardiol 49: 2120-2128, 2007.
13. Kono T, Rosman H, Alam M, Stein PD, Sabbah HN. Hemodynamic correlates of the third heart sound during the evolution of chronic heart failure. J Am Coll Cardiol 21: 419-423, 1993.
14. Kono T, Sabbah HN, Rosman H, Alam M, Stein PD, Goldstein S. Left atrial contribution to ventricular filling during the course of evolving heart failure. Circulation 86: 1317-1322, 1992.
15. Maltsev VA, Silverman N, Sabbah HN, Undrovinas AI. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. Eur J Heart Fail 9: 219-227, 2007.
16. Morita H, Khanal S, Rastogi S, Suzuki G, Imai M, Todor A, Sharov VG, Goldstein S, O'Neill TP, Sabbah HN. Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Am J Physiol Heart Circ Physiol 290: H2522-H2527, 2006.
17. Morita H, Suzuki G, Mishima T, Chaudhry PA, Anagnostopoulos PV, Tanhehco EJ, Sharov VG, Goldstein S, Sabbah HN. Effects of longterm monotherapy with metoprolol CR/XL on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Cardiovasc Drugs Ther 16: 443-449, 2002.
18. Pham DQ, Mehta M. Ranolazine: a novel agent that improves dysfunctional sodium channels. Int J Clin Pract 61: 864-872, 2007.
19. i handling in the failing human heart. Cardiovasc Res 57: 874-886, 2003.
20. Rastogi S, Mishra S, Zaca V, Alesh I, Gupta RC, Goldstein S, Sabbah HN. Effect of long-term monotherapy with the aldosterone receptor blocker eplerenone on cytoskeletal proteins and matrix metalloproteinases in dogs with heart failure. Cardiovasc Drugs Ther 21: 415-422, 2007.
21. Rastogi S, Mishra S, Zaca V, Mika Y, Rousso B, Sabbah HN. Effects of chronic therapy with cardiac contractility modulation electrical signals on cytoskeletal proteins and matrix metalloproteinases in dogs with heart failure. Cardiology 110: 230-237, 2007.
22. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 95: 311-316, 2005.
23. Sabbah HN, Chandler MP, Mishima T, Suzuki G, Chaudhry P, Nass O, Biesiadecki BJ, Blackburn B, Wolff A, Stanley WC. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 8: 416-422, 2002.
24. Sabbah HN, Goldberg AD, Schoels W, Kono T, Webb C, Brachmann J, Goldstein S. Spontaneous and inducible ventricular arrhythmias in a canine model of chronic heart failure: relation to haemodynamics and sympathoadrenergic activation. Eur Heart J 13: 1562-1572, 1992.
25. Sabbah HN, Hansen-Smith F, Sharov VG, Kono T, Lesch M, Gengo PJ, Steffen RP, Levine TB, Goldstein S. Decreased proportion of type I myofibers in skeletal muscle of dogs with chronic heart failure. Circulation 87: 1729-1737, 1993.
26. Sabbah HN, Imai M, Cowart D, Amato A, Carminati P, Gheorghiade M. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure. Am J Cardiol 99: 41A-46A, 2007.
27. Sabbah HN, Kono T, Rosman H, Jafri S, Stein PD, Goldstein S. Left ventricular shape: a factor in the etiology of functional mitral regurgitation in heart failure. Am Heart J 123: 961-966, 1992.
28. Sabbah HN, Kono T, Stein PD, Mancini GB, Goldstein S. Left ventricular shape changes during the course of evolving heart failure. Am J Physiol Heart Circ Physiol 263: H266-H270, 1992.
29. Sabbah HN, Levine TB, Gheorghiade M, Kono T, Goldstein S. Hemodynamic response of a canine model of chronic heart failure to intravenous dobutamine, nitroprusside, enalaprilat, and digoxin. Cardiovasc Drugs Ther 7: 349-356, 1993.
30. Sabbah HN, Sharov V, Riddle JM, Kono T, Lesch M, Goldstein S. Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 24: 1333-1347, 1992.
31. Sabbah HN, Sharov VG, Gupta RC, Mishra S, Rastogi S, Undrovinas AI, Chaudhry PA, Todor A, Mishima T, Tanhehco EJ, Suzuki G. Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. Circ Res 93: 1095-1101, 2003.
32. Sabbah HN, Sharov VG, Lesch M, Goldstein S. Progression of heart failure: a role for interstitial fibrosis. Mol Cell Biochem 147: 29-34, 1995.
33. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, Goldstein S. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 89: 2852-2859, 1994.
34. Sabbah HN, Stanley WC, Sharov VG, Mishima T, Tanimura M, Benedict CR, Hegde S, Goldstein S. Effects of dopamine beta-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Circulation 102: 1990-1995, 2000.
35. Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S, Hawkins ET, Goldstein S. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol Heart Circ Physiol 260: H1379-H1384, 1991.
36. Shimoyama H, Sabbah HN, Rosman H, Kono T, Alam M, Goldstein S. Effects of long-term therapy with enalapril on severity of functional mitral regurgitation in dogs with moderate heart failure. J Am Coll Cardiol 25: 768-772, 1995.
37. Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther 318: 214-222, 2006.
38. Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 44: 192-199, 2004.
39. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 48: 566-575, 2006.
40. Suzuki G, Morita H, Mishima T, Sharov VG, Todor A, Tanhehco EJ, Rudolph AE, McMahon EG, Goldstein S, Sabbah HN. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106: 2967-2972, 2002.
41. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation 110: 894-896, 2004.
42. Tanimura M, Sharov VG, Shimoyama H, Mishima T, Levine TB, Goldstein S, Sabbah HN. Effects of AT1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure. Am J Physiol Heart Circ Physiol 276: H1385-H1392, 1999.
43. 2+-ATPase in ventricular myocytes from transgenic mice. Cardiovasc Res 49: 38-47, 2001.
44. 2+ exchanger. J Physiol 512: 651-667, 1998.
45. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 17, Suppl 1: S169-S177, 2006.
46. Undrovinas AI, Maltsev VA, Sabbah HN. Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current. Cell Mol Life Sci 55: 494-505, 1999.
47. Valdivia CR, Chu WW, Pu J, Foell JD, Haworth RA, Wolff MR, Kamp TJ, Makielski JC. Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J Mol Cell Cardiol 38: 475-483, 2005.
48. Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, Chatham JC. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther 321: 213-220, 2007.
49. Zaca V, Rastogi S, Imai M, Wang M, Sharov VG, Jiang A, Goldstein S, Sabbah HN. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 50: 551-557, 2007.